Information about COMPOUNDED Semaglutide

Being overweight or obese has a negative impact on overall health due to accumulation of excess body fat leading to chronic health conditions. Obesity may range from asymptomatic to presentation complicated by multiple comorbidities including hypertension, diabetes, cancer, coronary artery disease, gout, obstructive sleep apnea, and osteoarthritis.

Clinical trials and extensive studies have shown Semaglutide (GLP-1 receptor agonist) is safe and effective in promoting weight loss, improving glycemic control without causing blood glucose drops, and reducing cardiovascular risk in people with type 2 diabetes. GLP-1 receptor agonists have been shown to have neuroprotective effects and may be helpful in treating neurodegenerative diseases such as Alzheimer's disease.  In addition, GLP-1 receptor agonists have shown to have anti-inflammatory effects which may help reduce inflammation and prevent the development of chronic diseases, such as cardiovascular disease and type 2 diabetes.  In overweight patients with PCOS, GLP-1 receptor agonists have shown to reduce body mass, reduce insulin resistance and help with normalization of menstrual cycles.

Semaglutide GLP-1, or glucagon-like peptide-1 is a naturally occurring peptide hormone that is secreted by the intestinal L-cells in response to food intake. It plays a critical role in regulating blood sugar levels by stimulating insulin secretion and reducing glucagon secretion resulting in improved glycemic control in people with type 2 diabetes. Semaglutide helps control hunger by mimicking the effects of GLP-1 which regulates appetite, slows down gastric emptying and increases satiety. In addition, GLP-1 also helps improve metabolic health and reduce the risk of cardiovascular disease. 

Potential side effects may include nausea, diarrhea, constipation, abdominal pain, and localized injection site redness. These side effects are typically mild and improve over time.

Compounded Semaglutide marketed under the brand Ozempic is administered by injection into the subcutaneous tissue (typically abdomen) weekly or based on the individuals needs and health status. 

This weekly injection increases feeling of fullness, lowers appetite, leading to lower caloric intake and ultimately weight loss. Clinical trials have demonstrated significant weight loss results with Semaglutide where participants lost an average of 14.9% of their body weight. 

Weight loss medication such as Semaglutide administered under the supervision of a trained provider increases the likelihood of weight loss and sustained results with lifestyle changes including healthy diet and regular exercise.

Pricing available upon consultation